Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.77 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576859 | 0.89 | CYP11B1 (0.81) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3575144 | 0.89 | CYP11B2 (0.64) | CYP11B2CYP11B1ALDH1A1FNTAFNTB | |
| Hydrochloric Acid SCHEMBL3567457 | 0.88 | CYP11B2 (0.62) | CYP11B2CYP11B1ALDH1A1FNTAFNTB | |
| SCHEMBL3567225 | 0.88 | CYP11B1 (0.83) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3570587 | 0.87 | CYP11B1 (0.57) | CYP11B2CYP11B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3578533 | 0.87 | CYP11B1 (0.81) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3572973 | 0.87 | CYP11B1 (0.81) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3574101 | 0.87 | CYP11B1 (0.84) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3574602 | 0.87 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3571991 | 0.85 | CYP11B1 (0.56) | CYP11B2CYP11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| EP-1537114-B8 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1537114-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | CYP11B2 6/4885CYP11B1 1/4885ALDH1A1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.